Investigating alendronate therapy for bone pain in adults with sickle cell disease
A feasibility study of alendronate therapy for osteonecrosis of the femoral head in adults with sickle cell disease
This study is looking at whether the medication alendronate, usually used for osteoporosis, can help reduce bone pain and improve the quality of life for adults with sickle cell disease who have a painful condition called osteonecrosis of the femoral head.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-10929314 on NIH RePORTER |
What this research studies
This research explores the use of alendronate, a medication typically used for osteoporosis, to treat osteonecrosis of the femoral head (ONFH) in adults with sickle cell disease (SCD). ONFH is a painful condition that affects many individuals with SCD, leading to chronic pain and disability. The study aims to assess the feasibility of using alendronate to alleviate bone pain and improve quality of life for these patients. Participants will be monitored over a six-month period to evaluate their pain levels and overall health outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults with sickle cell disease who are experiencing osteonecrosis of the femoral head.
Not a fit: Patients without sickle cell disease or those who do not have osteonecrosis of the femoral head may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option to significantly reduce pain and improve the quality of life for adults suffering from ONFH due to sickle cell disease.
How similar studies have performed: Previous research has shown that alendronate can be effective in treating bone pain in other conditions, suggesting potential for success in this novel application.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Adesina, Oyebimpe Oluyemisi — University of California at Davis
- Study coordinator: Adesina, Oyebimpe Oluyemisi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.